The EED Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population with targeted disruption of the EED gene in the human liver adenocarcinoma cell line SK-HEP-1. This loss-of-function model provides a robust system for studying EED-dependent epigenetic regulation and PRC2-mediated gene silencing, offering a heterogeneous polyclonal background ideal for functional genomics and drug screening.
The SK-HEP-1 cell line is an epithelial line originally derived from ascites of a liver adenocarcinoma patient. As a model of cancerous liver epithelial cells, it is extensively used in hepatocellular carcinoma research to investigate tumorigenesis, metastasis, and therapeutic responses. The adherent epithelial morphology and malignant characteristics of SK-HEP-1 cells facilitate diverse experimental manipulations, making them a robust platform for loss-of-function studies.
EED is a core subunit of PRC2 that binds H3K27me3 and allosterically activates the methyltransferase EZH2, driving propagation of repressive histone marks and transcriptional silencing. This allosteric activation is essential for the spreading of H3K27me3 domains and stable gene repression, thereby controlling cell fate decisions, differentiation, and oncogenic transformation. It forms complexes with SUZ12, RBBP4/RBBP7, and interacts with regulatory factors JARID2, AEBP2, and PHF1. EED expression is influenced by developmental cues including retinoic acid and Wnt signaling. Key PRC2 target genes silenced by H3K27me3 include HOX clusters and tumor suppressors CDKN2A and CDKN1A, whose repression is critical for maintaining the undifferentiated state and oncogenic potential.
In the liver adenocarcinoma context, disruption of EED eliminates PRC2 catalytic function, resulting in loss of H3K27me3 and reactivation of silenced tumor suppressors. This renders SK-HEP-1 cells vulnerable to apoptosis and reduced proliferation, highlighting EED’s role in sustaining the malignant phenotype. Furthermore, EED knockout can synergize with existing chemotherapeutics or targeted agents, providing a platform to identify combination strategies. The model is thus valuable for exploring epigenetic dependencies in hepatocellular carcinoma and for assessing sensitivity to PRC2-targeted therapies, such as EZH2 inhibitors.
Research applications include western blotting and ChIP-qPCR to monitor H3K27me3 levels and target gene occupancy, RNA-seq for transcriptome-wide analysis, and functional assays such as proliferation, migration, invasion, apoptosis, and spheroid formation. In addition, these cells can be used in chromatin remodeling studies and to dissect the role of PRC2 in epithelial-mesenchymal transition and metastasis. Drug sensitivity profiling with EZH2 inhibitors like tazemetostat can be performed to study therapeutic vulnerabilities. For further technical details, please contact Ascent Research.
